Anthony Elias
Concepts (631)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 108 | 2024 | 2142 | 6.380 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 95 | 2024 | 1565 | 3.830 |
Why?
| Sarcoma | 32 | 2022 | 176 | 3.210 |
Why?
| Receptors, Estrogen | 22 | 2021 | 426 | 2.380 |
Why?
| Triple Negative Breast Neoplasms | 14 | 2024 | 197 | 2.330 |
Why?
| Receptor, ErbB-2 | 22 | 2024 | 326 | 2.100 |
Why?
| Hematopoietic Stem Cell Transplantation | 36 | 2011 | 573 | 2.080 |
Why?
| Carcinoma, Small Cell | 19 | 2003 | 169 | 1.760 |
Why?
| Soft Tissue Neoplasms | 14 | 2022 | 112 | 1.620 |
Why?
| Carcinoma, Ductal, Breast | 7 | 2018 | 82 | 1.530 |
Why?
| Neoadjuvant Therapy | 17 | 2024 | 383 | 1.380 |
Why?
| Antineoplastic Agents | 31 | 2023 | 2061 | 1.290 |
Why?
| Neoplasm Recurrence, Local | 20 | 2022 | 964 | 1.250 |
Why?
| Neoplasm Staging | 35 | 2024 | 1295 | 1.110 |
Why?
| Receptors, Progesterone | 13 | 2020 | 343 | 1.080 |
Why?
| Lung Neoplasms | 38 | 2003 | 2344 | 1.080 |
Why?
| Combined Modality Therapy | 52 | 2024 | 1206 | 1.040 |
Why?
| Biomarkers, Tumor | 17 | 2022 | 1181 | 1.020 |
Why?
| Paclitaxel | 14 | 2024 | 217 | 0.940 |
Why?
| Mastectomy | 9 | 2018 | 131 | 0.930 |
Why?
| Bone Marrow Transplantation | 27 | 1998 | 274 | 0.930 |
Why?
| Bone Neoplasms | 7 | 2025 | 231 | 0.880 |
Why?
| Doxorubicin | 23 | 2024 | 325 | 0.840 |
Why?
| Antineoplastic Agents, Alkylating | 5 | 2018 | 69 | 0.770 |
Why?
| Female | 167 | 2025 | 68776 | 0.750 |
Why?
| Receptors, Androgen | 7 | 2018 | 147 | 0.750 |
Why?
| Disease-Free Survival | 24 | 2023 | 648 | 0.740 |
Why?
| Antibodies, Monoclonal, Humanized | 9 | 2024 | 759 | 0.710 |
Why?
| Humans | 222 | 2025 | 129650 | 0.700 |
Why?
| Antineoplastic Agents, Hormonal | 10 | 2018 | 158 | 0.690 |
Why?
| Maytansine | 3 | 2021 | 16 | 0.670 |
Why?
| Liposarcoma | 4 | 2023 | 27 | 0.670 |
Why?
| Middle Aged | 110 | 2025 | 31154 | 0.670 |
Why?
| Neoplasm Metastasis | 23 | 2024 | 610 | 0.620 |
Why?
| Chemotherapy, Adjuvant | 23 | 2023 | 381 | 0.600 |
Why?
| Dioxoles | 2 | 2015 | 9 | 0.580 |
Why?
| Tetrahydroisoquinolines | 2 | 2015 | 8 | 0.580 |
Why?
| Cyclophosphamide | 31 | 2024 | 232 | 0.580 |
Why?
| Adult | 111 | 2025 | 35576 | 0.570 |
Why?
| Ifosfamide | 19 | 1998 | 34 | 0.530 |
Why?
| Androgen Receptor Antagonists | 6 | 2021 | 36 | 0.530 |
Why?
| Phenylthiohydantoin | 5 | 2017 | 44 | 0.530 |
Why?
| Dasatinib | 1 | 2016 | 54 | 0.520 |
Why?
| Trastuzumab | 10 | 2024 | 101 | 0.510 |
Why?
| Neoplasms, Hormone-Dependent | 3 | 2012 | 38 | 0.500 |
Why?
| Treatment Outcome | 43 | 2024 | 10230 | 0.490 |
Why?
| Aged | 63 | 2025 | 22103 | 0.490 |
Why?
| Estrogen Receptor alpha | 5 | 2021 | 133 | 0.470 |
Why?
| Drug Administration Schedule | 24 | 2018 | 769 | 0.460 |
Why?
| Carboplatin | 21 | 2016 | 140 | 0.460 |
Why?
| Granulocyte Colony-Stimulating Factor | 11 | 2002 | 72 | 0.460 |
Why?
| Carcinoma, Non-Small-Cell Lung | 17 | 2001 | 1052 | 0.440 |
Why?
| Clinical Trials as Topic | 19 | 2018 | 1004 | 0.440 |
Why?
| Estrogens | 6 | 2018 | 347 | 0.420 |
Why?
| Dacarbazine | 9 | 2018 | 94 | 0.400 |
Why?
| Neoplasms | 20 | 2009 | 2470 | 0.390 |
Why?
| Survival Rate | 19 | 2021 | 1877 | 0.380 |
Why?
| Tamoxifen | 9 | 2018 | 200 | 0.380 |
Why?
| Survival Analysis | 23 | 2010 | 1274 | 0.370 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 958 | 0.360 |
Why?
| Pyrimidines | 3 | 2020 | 459 | 0.350 |
Why?
| Antibodies, Monoclonal | 9 | 2024 | 1367 | 0.350 |
Why?
| Neoplasms, Second Primary | 3 | 2022 | 106 | 0.350 |
Why?
| Carcinoma, Intraductal, Noninfiltrating | 3 | 2022 | 54 | 0.340 |
Why?
| Prognosis | 21 | 2021 | 3794 | 0.340 |
Why?
| Dose-Response Relationship, Drug | 17 | 2017 | 2012 | 0.340 |
Why?
| Granulocyte-Macrophage Colony-Stimulating Factor | 8 | 1999 | 147 | 0.340 |
Why?
| Taxoids | 7 | 2023 | 98 | 0.330 |
Why?
| Remission Induction | 16 | 2002 | 272 | 0.330 |
Why?
| Breast Neoplasms, Male | 3 | 2018 | 29 | 0.330 |
Why?
| Drug Resistance, Neoplasm | 7 | 2017 | 759 | 0.320 |
Why?
| Gene Expression Regulation, Neoplastic | 11 | 2018 | 1356 | 0.300 |
Why?
| Neoplastic Cells, Circulating | 2 | 2020 | 71 | 0.300 |
Why?
| Mesna | 12 | 1998 | 15 | 0.290 |
Why?
| Sarcoma, Ewing | 3 | 2022 | 89 | 0.280 |
Why?
| Leiomyosarcoma | 2 | 2018 | 27 | 0.270 |
Why?
| Cisplatin | 14 | 2000 | 300 | 0.270 |
Why?
| Immunoconjugates | 3 | 2024 | 103 | 0.270 |
Why?
| Sternum | 1 | 2006 | 25 | 0.260 |
Why?
| Tumor Microenvironment | 4 | 2024 | 634 | 0.260 |
Why?
| Immunohistochemistry | 5 | 2016 | 1698 | 0.260 |
Why?
| Mastectomy, Segmental | 2 | 2009 | 85 | 0.250 |
Why?
| Pyridines | 2 | 2025 | 478 | 0.250 |
Why?
| Chondrosarcoma | 1 | 2025 | 15 | 0.240 |
Why?
| Peripheral Blood Stem Cell Transplantation | 2 | 2002 | 21 | 0.240 |
Why?
| Carcinoma, Ductal | 1 | 2005 | 11 | 0.240 |
Why?
| Transplantation, Autologous | 19 | 2002 | 211 | 0.240 |
Why?
| Melphalan | 10 | 2002 | 29 | 0.240 |
Why?
| Isocitrate Dehydrogenase | 1 | 2025 | 52 | 0.240 |
Why?
| Protein Kinase Inhibitors | 4 | 2019 | 891 | 0.230 |
Why?
| Cell Adhesion Molecules | 2 | 2021 | 173 | 0.230 |
Why?
| Lymph Nodes | 1 | 2007 | 472 | 0.230 |
Why?
| Carcinoma | 2 | 2008 | 217 | 0.230 |
Why?
| Glycine | 1 | 2025 | 165 | 0.220 |
Why?
| Risk Reduction Behavior | 2 | 2016 | 209 | 0.220 |
Why?
| Ovarian Neoplasms | 3 | 2022 | 490 | 0.220 |
Why?
| Drug Evaluation | 19 | 1998 | 82 | 0.220 |
Why?
| Adjuvants, Immunologic | 3 | 2022 | 221 | 0.220 |
Why?
| Deoxycytidine | 4 | 2020 | 165 | 0.220 |
Why?
| Survivors | 3 | 2016 | 464 | 0.220 |
Why?
| Ribonuclease III | 2 | 2016 | 37 | 0.210 |
Why?
| Hodgkin Disease | 4 | 2016 | 134 | 0.210 |
Why?
| Thiotepa | 13 | 2002 | 20 | 0.210 |
Why?
| Alkylating Agents | 3 | 2000 | 24 | 0.210 |
Why?
| Weight Loss | 4 | 2016 | 734 | 0.210 |
Why?
| Behavior Therapy | 2 | 2016 | 241 | 0.210 |
Why?
| DEAD-box RNA Helicases | 2 | 2016 | 66 | 0.210 |
Why?
| Male | 65 | 2025 | 63681 | 0.210 |
Why?
| Triazoles | 2 | 2022 | 152 | 0.200 |
Why?
| Medical Oncology | 5 | 2024 | 272 | 0.200 |
Why?
| Gene Expression Profiling | 6 | 2017 | 1706 | 0.200 |
Why?
| Disease Management | 5 | 2020 | 589 | 0.200 |
Why?
| Employment | 1 | 2024 | 167 | 0.200 |
Why?
| Mutation | 4 | 2025 | 3717 | 0.200 |
Why?
| Obesity | 4 | 2018 | 2883 | 0.200 |
Why?
| Overweight | 3 | 2016 | 531 | 0.200 |
Why?
| Aged, 80 and over | 13 | 2021 | 7086 | 0.190 |
Why?
| Salvage Therapy | 6 | 2010 | 134 | 0.190 |
Why?
| Circulating Tumor DNA | 1 | 2022 | 28 | 0.190 |
Why?
| Hydrazines | 1 | 2022 | 34 | 0.190 |
Why?
| Referral and Consultation | 1 | 2007 | 732 | 0.190 |
Why?
| Carcinoma in Situ | 2 | 2012 | 45 | 0.190 |
Why?
| Etoposide | 10 | 2001 | 148 | 0.190 |
Why?
| Emergency Medicine | 1 | 2024 | 215 | 0.190 |
Why?
| Hematologic Diseases | 6 | 2008 | 61 | 0.190 |
Why?
| Tumor Cells, Cultured | 9 | 2020 | 940 | 0.190 |
Why?
| Sarcoma, Synovial | 1 | 2021 | 17 | 0.190 |
Why?
| Liposarcoma, Myxoid | 1 | 2021 | 9 | 0.190 |
Why?
| Aromatase Inhibitors | 4 | 2021 | 51 | 0.180 |
Why?
| Recombinant Fusion Proteins | 1 | 2024 | 643 | 0.180 |
Why?
| Endpoint Determination | 1 | 2021 | 76 | 0.180 |
Why?
| Sentinel Lymph Node Biopsy | 3 | 2017 | 107 | 0.170 |
Why?
| Cancer Care Facilities | 1 | 2020 | 32 | 0.170 |
Why?
| Time Factors | 12 | 2020 | 6556 | 0.170 |
Why?
| Hematopoietic Stem Cells | 5 | 1996 | 381 | 0.170 |
Why?
| Indazoles | 1 | 2020 | 65 | 0.170 |
Why?
| Leukocytes, Mononuclear | 3 | 2020 | 545 | 0.170 |
Why?
| Cell Separation | 3 | 2017 | 316 | 0.170 |
Why?
| Diphosphonates | 1 | 2020 | 58 | 0.170 |
Why?
| Pyrroles | 2 | 2013 | 202 | 0.160 |
Why?
| Diet | 3 | 2018 | 1213 | 0.160 |
Why?
| Bone Marrow | 8 | 2000 | 271 | 0.160 |
Why?
| Cell Line, Tumor | 9 | 2017 | 3215 | 0.160 |
Why?
| Antigens, Neoplasm | 4 | 2021 | 309 | 0.160 |
Why?
| Proportional Hazards Models | 6 | 2020 | 1201 | 0.160 |
Why?
| MCF-7 Cells | 5 | 2017 | 116 | 0.150 |
Why?
| Fluorouracil | 7 | 2013 | 199 | 0.150 |
Why?
| CA-125 Antigen | 2 | 2013 | 15 | 0.150 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2020 | 202 | 0.150 |
Why?
| Benzamides | 5 | 2017 | 207 | 0.150 |
Why?
| Nitriles | 5 | 2017 | 172 | 0.150 |
Why?
| Bayes Theorem | 4 | 2024 | 375 | 0.150 |
Why?
| Research Design | 3 | 2021 | 1044 | 0.150 |
Why?
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2018 | 52 | 0.150 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2020 | 232 | 0.150 |
Why?
| Cyclin-Dependent Kinase 4 | 1 | 2018 | 44 | 0.150 |
Why?
| Cell Cycle | 1 | 2021 | 592 | 0.150 |
Why?
| Cyclin-Dependent Kinase 6 | 1 | 2018 | 40 | 0.140 |
Why?
| Indoles | 2 | 2013 | 387 | 0.140 |
Why?
| Infusions, Intravenous | 10 | 2020 | 400 | 0.140 |
Why?
| Kaplan-Meier Estimate | 6 | 2018 | 857 | 0.140 |
Why?
| Fibromatosis, Aggressive | 1 | 2017 | 17 | 0.140 |
Why?
| Tetrahydronaphthalenes | 1 | 2017 | 30 | 0.140 |
Why?
| Vaccines | 1 | 2022 | 398 | 0.140 |
Why?
| Microbubbles | 1 | 2017 | 48 | 0.140 |
Why?
| Valine | 1 | 2017 | 81 | 0.140 |
Why?
| Camptothecin | 3 | 2024 | 109 | 0.140 |
Why?
| Lymph Node Excision | 3 | 2015 | 164 | 0.140 |
Why?
| Immunotherapy | 2 | 2018 | 592 | 0.140 |
Why?
| Internship and Residency | 2 | 2024 | 1053 | 0.140 |
Why?
| Amyloid Precursor Protein Secretases | 1 | 2017 | 80 | 0.130 |
Why?
| Sulfonamides | 1 | 2020 | 496 | 0.130 |
Why?
| Axilla | 3 | 2017 | 45 | 0.130 |
Why?
| Androgen Antagonists | 2 | 2015 | 79 | 0.130 |
Why?
| Cancer-Associated Fibroblasts | 1 | 2016 | 13 | 0.130 |
Why?
| Gonadal Steroid Hormones | 1 | 2018 | 131 | 0.130 |
Why?
| Neoplasms, Radiation-Induced | 1 | 2016 | 71 | 0.130 |
Why?
| Neoplasms, Germ Cell and Embryonal | 2 | 1995 | 69 | 0.130 |
Why?
| Hematopoietic Cell Growth Factors | 2 | 1995 | 4 | 0.130 |
Why?
| Follow-Up Studies | 6 | 2025 | 4897 | 0.130 |
Why?
| Ultrasonography, Mammary | 1 | 2016 | 12 | 0.130 |
Why?
| Lymphatic Metastasis | 3 | 2017 | 320 | 0.130 |
Why?
| Thiazoles | 1 | 2016 | 117 | 0.130 |
Why?
| Antibody Specificity | 1 | 2016 | 184 | 0.130 |
Why?
| Tumor Suppressor Protein p53 | 2 | 2023 | 511 | 0.130 |
Why?
| Neoplasm Invasiveness | 3 | 2016 | 485 | 0.130 |
Why?
| Maximum Tolerated Dose | 1 | 2016 | 193 | 0.120 |
Why?
| Antibiotics, Antineoplastic | 1 | 2016 | 123 | 0.120 |
Why?
| Neoplastic Stem Cells | 2 | 2017 | 380 | 0.120 |
Why?
| Quinolines | 1 | 2016 | 156 | 0.120 |
Why?
| Benzimidazoles | 1 | 2016 | 162 | 0.120 |
Why?
| Pyrazoles | 1 | 2018 | 405 | 0.120 |
Why?
| Recurrence | 5 | 2020 | 1007 | 0.120 |
Why?
| Mammography | 1 | 2016 | 146 | 0.120 |
Why?
| Drug Therapy, Combination | 4 | 2014 | 1040 | 0.110 |
Why?
| Disease Progression | 7 | 2018 | 2635 | 0.110 |
Why?
| Radiotherapy, Adjuvant | 5 | 2016 | 210 | 0.110 |
Why?
| Homeodomain Proteins | 2 | 2018 | 495 | 0.110 |
Why?
| Administration, Oral | 4 | 2020 | 786 | 0.110 |
Why?
| Young Adult | 10 | 2025 | 12426 | 0.110 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2017 | 396 | 0.110 |
Why?
| Antibodies | 1 | 2016 | 398 | 0.110 |
Why?
| Societies, Medical | 1 | 2018 | 751 | 0.110 |
Why?
| Exercise | 2 | 2015 | 1925 | 0.110 |
Why?
| Brain Edema | 1 | 2014 | 60 | 0.110 |
Why?
| Hepatic Veno-Occlusive Disease | 3 | 2002 | 14 | 0.110 |
Why?
| Radiotherapy Dosage | 3 | 1999 | 252 | 0.110 |
Why?
| Animals | 16 | 2021 | 35361 | 0.110 |
Why?
| Poly(ADP-ribose) Polymerase Inhibitors | 3 | 2022 | 90 | 0.110 |
Why?
| Comorbidity | 5 | 2017 | 1547 | 0.110 |
Why?
| Vascular Neoplasms | 1 | 2013 | 17 | 0.110 |
Why?
| Radiotherapy | 3 | 2015 | 188 | 0.110 |
Why?
| Testicular Neoplasms | 1 | 1995 | 104 | 0.110 |
Why?
| Epigenesis, Genetic | 2 | 2018 | 613 | 0.110 |
Why?
| Clinical Trials, Phase I as Topic | 3 | 2024 | 50 | 0.110 |
Why?
| Mice | 12 | 2021 | 16937 | 0.110 |
Why?
| Adenocarcinoma | 6 | 2015 | 898 | 0.100 |
Why?
| Cellular Reprogramming | 1 | 2014 | 95 | 0.100 |
Why?
| Keratins | 2 | 2017 | 175 | 0.100 |
Why?
| Bridged-Ring Compounds | 3 | 2020 | 12 | 0.100 |
Why?
| Mercaptoethanol | 2 | 1990 | 11 | 0.100 |
Why?
| Patient Selection | 4 | 2016 | 663 | 0.100 |
Why?
| Apoptosis | 6 | 2023 | 2503 | 0.100 |
Why?
| Cell Proliferation | 6 | 2017 | 2391 | 0.100 |
Why?
| Gallium Radioisotopes | 1 | 1992 | 14 | 0.100 |
Why?
| Bone Marrow Cells | 4 | 2000 | 300 | 0.100 |
Why?
| Chromatin | 1 | 2016 | 479 | 0.100 |
Why?
| Adolescent | 23 | 2025 | 20393 | 0.100 |
Why?
| Carmustine | 10 | 2001 | 50 | 0.100 |
Why?
| Lymphoma, Non-Hodgkin | 3 | 2001 | 77 | 0.100 |
Why?
| Protein-Tyrosine Kinases | 2 | 2022 | 432 | 0.100 |
Why?
| Retrospective Studies | 12 | 2023 | 14518 | 0.100 |
Why?
| Anthracyclines | 3 | 2023 | 49 | 0.100 |
Why?
| Brain Neoplasms | 5 | 2014 | 1171 | 0.090 |
Why?
| Methotrexate | 4 | 2002 | 249 | 0.090 |
Why?
| Liver Neoplasms | 3 | 2015 | 640 | 0.090 |
Why?
| Weight Reduction Programs | 1 | 2012 | 111 | 0.090 |
Why?
| Neoplasm, Residual | 2 | 2022 | 120 | 0.090 |
Why?
| Radiosurgery | 1 | 2014 | 321 | 0.090 |
Why?
| RNA, Catalytic | 1 | 2012 | 185 | 0.090 |
Why?
| Polydeoxyribonucleotides | 2 | 2002 | 13 | 0.090 |
Why?
| Aorta | 1 | 2013 | 411 | 0.090 |
Why?
| Neutropenia | 5 | 2013 | 136 | 0.090 |
Why?
| Neoplasm Grading | 3 | 2017 | 285 | 0.090 |
Why?
| Carcinoma, Lobular | 1 | 2011 | 48 | 0.090 |
Why?
| Leukapheresis | 4 | 2001 | 21 | 0.090 |
Why?
| Multivariate Analysis | 4 | 2013 | 1502 | 0.090 |
Why?
| Angiogenesis Inhibitors | 1 | 2012 | 220 | 0.080 |
Why?
| Keratin-5 | 1 | 2010 | 50 | 0.080 |
Why?
| Biopsy | 3 | 2018 | 1097 | 0.080 |
Why?
| Molecular Targeted Therapy | 3 | 2018 | 390 | 0.080 |
Why?
| Electrophoresis, Gel, Two-Dimensional | 1 | 2010 | 110 | 0.080 |
Why?
| Peptide Mapping | 1 | 2010 | 63 | 0.080 |
Why?
| Databases, Protein | 1 | 2010 | 62 | 0.080 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 137 | 0.080 |
Why?
| Urinary Tract | 1 | 1990 | 38 | 0.080 |
Why?
| Postmenopause | 2 | 2017 | 351 | 0.080 |
Why?
| Benzenesulfonates | 1 | 2009 | 19 | 0.080 |
Why?
| CD146 Antigen | 2 | 2021 | 41 | 0.080 |
Why?
| BRCA2 Protein | 1 | 2009 | 53 | 0.080 |
Why?
| Health Facilities | 1 | 2009 | 80 | 0.080 |
Why?
| Pregnancy Complications, Neoplastic | 1 | 2009 | 53 | 0.080 |
Why?
| Observer Variation | 1 | 2010 | 315 | 0.080 |
Why?
| Thrombophilia | 1 | 2009 | 81 | 0.080 |
Why?
| Patient Care | 1 | 2009 | 109 | 0.080 |
Why?
| United States | 9 | 2023 | 13903 | 0.080 |
Why?
| Perimenopause | 1 | 2008 | 60 | 0.070 |
Why?
| Fibrinolytic Agents | 2 | 2002 | 263 | 0.070 |
Why?
| Mice, Nude | 3 | 2017 | 683 | 0.070 |
Why?
| Randomized Controlled Trials as Topic | 6 | 2000 | 1368 | 0.070 |
Why?
| Fatigue | 3 | 2018 | 318 | 0.070 |
Why?
| Xenograft Model Antitumor Assays | 3 | 2017 | 814 | 0.070 |
Why?
| In Situ Hybridization | 2 | 2010 | 295 | 0.070 |
Why?
| Bone Marrow Diseases | 4 | 2000 | 19 | 0.070 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2008 | 315 | 0.070 |
Why?
| Risk Assessment | 2 | 2020 | 3240 | 0.070 |
Why?
| Blotting, Western | 1 | 2010 | 1205 | 0.070 |
Why?
| Reproducibility of Results | 2 | 2016 | 3083 | 0.070 |
Why?
| Pneumonectomy | 3 | 1997 | 151 | 0.070 |
Why?
| Sputum | 1 | 1988 | 302 | 0.070 |
Why?
| Quality of Life | 2 | 2015 | 2704 | 0.070 |
Why?
| Clinical Decision-Making | 2 | 2020 | 303 | 0.060 |
Why?
| Risk Factors | 7 | 2020 | 9765 | 0.060 |
Why?
| Neoplasm Proteins | 2 | 2007 | 424 | 0.060 |
Why?
| Life Tables | 2 | 2002 | 18 | 0.060 |
Why?
| Anilides | 2 | 2016 | 73 | 0.060 |
Why?
| Positron-Emission Tomography | 1 | 2006 | 288 | 0.060 |
Why?
| New Jersey | 1 | 2024 | 12 | 0.060 |
Why?
| Predictive Value of Tests | 2 | 2016 | 1952 | 0.060 |
Why?
| Colony-Stimulating Factors | 3 | 1988 | 35 | 0.060 |
Why?
| Enzyme Inhibitors | 1 | 2008 | 827 | 0.060 |
Why?
| Granulocytes | 4 | 1995 | 77 | 0.060 |
Why?
| Receptor, TIE-2 | 1 | 2024 | 12 | 0.060 |
Why?
| Genes, Neoplasm | 1 | 2004 | 20 | 0.060 |
Why?
| New York | 1 | 2024 | 128 | 0.060 |
Why?
| Ricin | 2 | 1997 | 8 | 0.060 |
Why?
| Growth Substances | 3 | 1988 | 152 | 0.060 |
Why?
| Oligonucleotide Array Sequence Analysis | 3 | 2012 | 769 | 0.060 |
Why?
| MicroRNAs | 1 | 2010 | 678 | 0.060 |
Why?
| Magnetic Resonance Imaging | 1 | 2016 | 3408 | 0.060 |
Why?
| Forecasting | 3 | 2000 | 359 | 0.050 |
Why?
| Patient Care Planning | 1 | 2005 | 149 | 0.050 |
Why?
| Thrombocytopenia | 3 | 2013 | 186 | 0.050 |
Why?
| Mammaplasty | 2 | 2016 | 98 | 0.050 |
Why?
| Signal Transduction | 5 | 2018 | 4925 | 0.050 |
Why?
| Up-Regulation | 2 | 2017 | 840 | 0.050 |
Why?
| Activating Transcription Factor 4 | 1 | 2023 | 20 | 0.050 |
Why?
| Proteasome Inhibitors | 1 | 2023 | 42 | 0.050 |
Why?
| Proteomics | 1 | 2010 | 1062 | 0.050 |
Why?
| Proto-Oncogene Proteins c-mdm2 | 1 | 2023 | 64 | 0.050 |
Why?
| Cyclin E | 1 | 2022 | 23 | 0.050 |
Why?
| G(M2) Ganglioside | 1 | 2022 | 1 | 0.050 |
Why?
| Injection Site Reaction | 1 | 2022 | 3 | 0.050 |
Why?
| Transcriptome | 2 | 2023 | 887 | 0.050 |
Why?
| Clinical Trials, Phase III as Topic | 2 | 2000 | 93 | 0.050 |
Why?
| Treatment Failure | 2 | 2001 | 340 | 0.050 |
Why?
| Proteasome Endopeptidase Complex | 1 | 2023 | 148 | 0.050 |
Why?
| Oncogene Proteins | 1 | 2022 | 55 | 0.050 |
Why?
| Luminescent Measurements | 1 | 2003 | 78 | 0.050 |
Why?
| Ribose | 1 | 2022 | 22 | 0.050 |
Why?
| Blood Transfusion, Autologous | 2 | 1993 | 16 | 0.050 |
Why?
| Carbolines | 1 | 2022 | 30 | 0.050 |
Why?
| Heterocyclic Compounds, 4 or More Rings | 1 | 2022 | 19 | 0.050 |
Why?
| Career Choice | 1 | 2024 | 207 | 0.050 |
Why?
| Adenosine Diphosphate | 1 | 2022 | 80 | 0.050 |
Why?
| Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 81 | 0.050 |
Why?
| Tomography, X-Ray Computed | 2 | 2015 | 2535 | 0.050 |
Why?
| Oncogenes | 1 | 2022 | 113 | 0.050 |
Why?
| Actuarial Analysis | 2 | 1993 | 26 | 0.050 |
Why?
| Colony-Forming Units Assay | 4 | 1996 | 90 | 0.050 |
Why?
| Cell Division | 2 | 2001 | 797 | 0.050 |
Why?
| Gene Expression | 2 | 2020 | 1472 | 0.050 |
Why?
| Carcinoembryonic Antigen | 1 | 2001 | 41 | 0.050 |
Why?
| Fellowships and Scholarships | 1 | 2024 | 273 | 0.040 |
Why?
| Phthalazines | 1 | 2021 | 41 | 0.040 |
Why?
| Prospective Studies | 5 | 2022 | 7133 | 0.040 |
Why?
| Age Factors | 3 | 2018 | 3144 | 0.040 |
Why?
| Longitudinal Studies | 2 | 2012 | 2717 | 0.040 |
Why?
| Clodronic Acid | 1 | 2020 | 12 | 0.040 |
Why?
| Transplantation Immunology | 1 | 2000 | 34 | 0.040 |
Why?
| Estradiol | 2 | 2016 | 494 | 0.040 |
Why?
| Extracellular Matrix | 1 | 2024 | 504 | 0.040 |
Why?
| Progesterone | 1 | 2002 | 245 | 0.040 |
Why?
| Ligands | 1 | 2022 | 622 | 0.040 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 359 | 0.040 |
Why?
| Topoisomerase I Inhibitors | 1 | 1999 | 16 | 0.040 |
Why?
| Thoracotomy | 2 | 1997 | 74 | 0.040 |
Why?
| Polymerase Chain Reaction | 1 | 2003 | 1038 | 0.040 |
Why?
| Leucovorin | 2 | 1997 | 69 | 0.040 |
Why?
| Bone Density Conservation Agents | 1 | 2020 | 70 | 0.040 |
Why?
| Hematopoietic Stem Cell Mobilization | 1 | 1999 | 22 | 0.040 |
Why?
| Dendritic Cells | 2 | 2000 | 478 | 0.040 |
Why?
| Mechlorethamine | 1 | 2000 | 63 | 0.040 |
Why?
| Myelodysplastic Syndromes | 1 | 2001 | 129 | 0.040 |
Why?
| Drug Resistance | 1 | 1999 | 166 | 0.040 |
Why?
| Neoplasms, Experimental | 1 | 2000 | 171 | 0.040 |
Why?
| Heterocyclic Compounds, 3-Ring | 1 | 2019 | 31 | 0.040 |
Why?
| Child | 8 | 2022 | 20883 | 0.040 |
Why?
| Cell Cycle Proteins | 1 | 2022 | 586 | 0.040 |
Why?
| Receptors, Steroid | 1 | 2019 | 49 | 0.040 |
Why?
| Cluster Analysis | 2 | 2012 | 482 | 0.040 |
Why?
| Piperazines | 1 | 2021 | 342 | 0.040 |
Why?
| Etanidazole | 1 | 1998 | 1 | 0.040 |
Why?
| Leukemia | 1 | 2001 | 230 | 0.040 |
Why?
| Loss of Function Mutation | 1 | 2018 | 39 | 0.040 |
Why?
| Enterocolitis, Pseudomembranous | 1 | 1998 | 28 | 0.040 |
Why?
| Expectorants | 1 | 1998 | 24 | 0.040 |
Why?
| Cross-Over Studies | 1 | 2020 | 521 | 0.040 |
Why?
| Aurora Kinase A | 1 | 2018 | 55 | 0.040 |
Why?
| Nervous System | 2 | 1997 | 67 | 0.040 |
Why?
| Retreatment | 1 | 2018 | 70 | 0.040 |
Why?
| Statistics, Nonparametric | 1 | 1999 | 422 | 0.040 |
Why?
| Disease Susceptibility | 1 | 2020 | 333 | 0.040 |
Why?
| Mediastinum | 1 | 1998 | 24 | 0.040 |
Why?
| Nausea | 1 | 2018 | 110 | 0.040 |
Why?
| Epithelial Cell Adhesion Molecule | 1 | 2017 | 10 | 0.040 |
Why?
| Administration, Intravenous | 1 | 2018 | 141 | 0.040 |
Why?
| Extremities | 2 | 1989 | 127 | 0.040 |
Why?
| Watchful Waiting | 1 | 2018 | 67 | 0.040 |
Why?
| SEER Program | 1 | 2018 | 206 | 0.040 |
Why?
| Breast | 1 | 2018 | 153 | 0.040 |
Why?
| Medicare | 1 | 2023 | 720 | 0.030 |
Why?
| Double-Blind Method | 1 | 2022 | 1876 | 0.030 |
Why?
| Diarrhea | 1 | 2018 | 180 | 0.030 |
Why?
| Cell Hypoxia | 1 | 1998 | 235 | 0.030 |
Why?
| Thorax | 1 | 1997 | 42 | 0.030 |
Why?
| Random Allocation | 2 | 1988 | 346 | 0.030 |
Why?
| Everolimus | 1 | 2017 | 88 | 0.030 |
Why?
| Cohort Studies | 4 | 2001 | 5420 | 0.030 |
Why?
| Phosphoramide Mustards | 1 | 2016 | 2 | 0.030 |
Why?
| Heterografts | 1 | 2017 | 131 | 0.030 |
Why?
| Immunotoxins | 1 | 1997 | 54 | 0.030 |
Why?
| Cyclohexanes | 1 | 2016 | 22 | 0.030 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 431 | 0.030 |
Why?
| Cell Survival | 1 | 2000 | 1086 | 0.030 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 1 | 1998 | 112 | 0.030 |
Why?
| Cytochrome P-450 CYP3A | 1 | 2017 | 87 | 0.030 |
Why?
| Placebos | 1 | 2016 | 201 | 0.030 |
Why?
| Gene Knockdown Techniques | 1 | 2017 | 315 | 0.030 |
Why?
| Carcinogenesis | 1 | 2018 | 213 | 0.030 |
Why?
| Injections, Intravenous | 2 | 1993 | 201 | 0.030 |
Why?
| Antineoplastic Agents, Immunological | 1 | 2018 | 181 | 0.030 |
Why?
| Blood Specimen Collection | 1 | 1995 | 35 | 0.030 |
Why?
| Fertility Preservation | 1 | 2016 | 53 | 0.030 |
Why?
| Organoplatinum Compounds | 3 | 1990 | 41 | 0.030 |
Why?
| Antidotes | 1 | 1997 | 136 | 0.030 |
Why?
| Mortality | 1 | 1997 | 307 | 0.030 |
Why?
| Blood Component Transfusion | 2 | 1994 | 82 | 0.030 |
Why?
| Genetic Therapy | 1 | 1997 | 292 | 0.030 |
Why?
| Digestive System | 1 | 1995 | 29 | 0.030 |
Why?
| Transcriptional Activation | 1 | 2017 | 366 | 0.030 |
Why?
| Vincristine | 1 | 1995 | 109 | 0.030 |
Why?
| Kidney | 2 | 1995 | 1385 | 0.030 |
Why?
| Fertility | 1 | 2016 | 160 | 0.030 |
Why?
| Interleukin-3 | 1 | 1994 | 23 | 0.030 |
Why?
| Hormones | 1 | 2015 | 140 | 0.030 |
Why?
| Weight Gain | 1 | 2018 | 510 | 0.030 |
Why?
| Child, Preschool | 6 | 2013 | 10517 | 0.030 |
Why?
| Pulmonary Fibrosis | 3 | 1993 | 386 | 0.030 |
Why?
| Bacterial Infections | 1 | 1996 | 237 | 0.030 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 253 | 0.030 |
Why?
| Adipose Tissue | 1 | 2018 | 592 | 0.030 |
Why?
| Odds Ratio | 1 | 2017 | 1023 | 0.030 |
Why?
| Leukocyte Count | 5 | 1996 | 326 | 0.030 |
Why?
| Tosyl Compounds | 1 | 2014 | 16 | 0.030 |
Why?
| Drug Discovery | 1 | 2015 | 131 | 0.030 |
Why?
| Hand-Foot Syndrome | 1 | 2013 | 2 | 0.030 |
Why?
| Protein Transport | 1 | 2015 | 428 | 0.030 |
Why?
| Capecitabine | 1 | 2013 | 46 | 0.030 |
Why?
| HEK293 Cells | 1 | 2016 | 697 | 0.030 |
Why?
| Transplantation, Heterologous | 1 | 2014 | 192 | 0.030 |
Why?
| Necrosis | 1 | 2014 | 232 | 0.030 |
Why?
| Neoplasm Transplantation | 1 | 2014 | 257 | 0.030 |
Why?
| Cell Nucleus | 1 | 2016 | 582 | 0.030 |
Why?
| Alternative Splicing | 1 | 2015 | 218 | 0.030 |
Why?
| Cross-Sectional Studies | 1 | 2024 | 5066 | 0.030 |
Why?
| Erythropoietin | 1 | 1994 | 86 | 0.030 |
Why?
| Binding Sites | 1 | 2016 | 1252 | 0.030 |
Why?
| Gene Silencing | 1 | 2014 | 190 | 0.030 |
Why?
| Blood Cells | 1 | 1993 | 39 | 0.030 |
Why?
| Nutritional Status | 1 | 2015 | 328 | 0.030 |
Why?
| Sensitivity and Specificity | 2 | 2000 | 1838 | 0.030 |
Why?
| Recombinant Proteins | 5 | 1997 | 1304 | 0.030 |
Why?
| Anemia | 1 | 1994 | 160 | 0.030 |
Why?
| CD24 Antigen | 1 | 2012 | 20 | 0.030 |
Why?
| Radionuclide Imaging | 1 | 1992 | 123 | 0.020 |
Why?
| Energy Intake | 1 | 2015 | 461 | 0.020 |
Why?
| Diet, Reducing | 1 | 2012 | 87 | 0.020 |
Why?
| Psychotherapy, Group | 1 | 2012 | 65 | 0.020 |
Why?
| Models, Biological | 1 | 1999 | 1722 | 0.020 |
Why?
| Hyaluronan Receptors | 1 | 2012 | 96 | 0.020 |
Why?
| Antigens, CD34 | 3 | 1996 | 88 | 0.020 |
Why?
| Counseling | 1 | 2015 | 385 | 0.020 |
Why?
| Surveys and Questionnaires | 1 | 2024 | 5406 | 0.020 |
Why?
| Feasibility Studies | 4 | 1998 | 868 | 0.020 |
Why?
| Mice, SCID | 1 | 2012 | 351 | 0.020 |
Why?
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 70 | 0.020 |
Why?
| Tumor Burden | 1 | 2012 | 286 | 0.020 |
Why?
| Fluorescent Antibody Technique | 2 | 1990 | 376 | 0.020 |
Why?
| Logistic Models | 1 | 2016 | 1988 | 0.020 |
Why?
| Disease Models, Animal | 1 | 2021 | 4063 | 0.020 |
Why?
| Biopsy, Needle | 1 | 2011 | 189 | 0.020 |
Why?
| Mice, Inbred NOD | 1 | 2012 | 588 | 0.020 |
Why?
| Colorado | 1 | 2020 | 4421 | 0.020 |
Why?
| Chromosomes, Human, Pair 9 | 1 | 1990 | 39 | 0.020 |
Why?
| Blast Crisis | 1 | 1990 | 33 | 0.020 |
Why?
| Chromosomes, Human, Pair 22 | 1 | 1990 | 41 | 0.020 |
Why?
| Bilirubin | 2 | 2002 | 96 | 0.020 |
Why?
| Health Status | 1 | 2015 | 755 | 0.020 |
Why?
| Immunoblotting | 1 | 2010 | 305 | 0.020 |
Why?
| Pemetrexed | 1 | 2010 | 32 | 0.020 |
Why?
| Glutamates | 1 | 2010 | 56 | 0.020 |
Why?
| Gene Regulatory Networks | 1 | 2012 | 284 | 0.020 |
Why?
| Kidney Diseases | 2 | 1991 | 384 | 0.020 |
Why?
| Graft Survival | 1 | 1993 | 512 | 0.020 |
Why?
| Cytokines | 1 | 1998 | 2017 | 0.020 |
Why?
| Magnetics | 1 | 1990 | 44 | 0.020 |
Why?
| Antibodies, Anti-Idiotypic | 1 | 1990 | 57 | 0.020 |
Why?
| Guanine | 1 | 2010 | 76 | 0.020 |
Why?
| Multiple Organ Failure | 2 | 2002 | 122 | 0.020 |
Why?
| Urologic Diseases | 1 | 1990 | 38 | 0.020 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2010 | 331 | 0.020 |
Why?
| Health Behavior | 1 | 2015 | 741 | 0.020 |
Why?
| Microspheres | 1 | 1990 | 127 | 0.020 |
Why?
| Chromosome Aberrations | 1 | 1990 | 150 | 0.020 |
Why?
| Spinal Cord Neoplasms | 1 | 1989 | 40 | 0.020 |
Why?
| Promoter Regions, Genetic | 1 | 2014 | 1207 | 0.020 |
Why?
| Blood | 1 | 1990 | 105 | 0.020 |
Why?
| Cell Movement | 1 | 2014 | 945 | 0.020 |
Why?
| Clone Cells | 1 | 1990 | 261 | 0.020 |
Why?
| Pregnancy Trimester, Second | 1 | 2009 | 77 | 0.020 |
Why?
| Lymphoma | 1 | 1990 | 196 | 0.020 |
Why?
| Hypertension | 1 | 2018 | 1242 | 0.020 |
Why?
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1990 | 118 | 0.020 |
Why?
| Central Nervous System Diseases | 1 | 1990 | 68 | 0.020 |
Why?
| Hematuria | 1 | 1989 | 12 | 0.020 |
Why?
| Vinblastine | 2 | 2001 | 69 | 0.020 |
Why?
| DNA Methylation | 1 | 2014 | 607 | 0.020 |
Why?
| False Negative Reactions | 1 | 1988 | 53 | 0.020 |
Why?
| Creatinine | 1 | 1991 | 491 | 0.020 |
Why?
| Pregnancy Trimester, First | 1 | 2009 | 138 | 0.020 |
Why?
| Histones | 1 | 2014 | 588 | 0.020 |
Why?
| Niacinamide | 1 | 2009 | 75 | 0.020 |
Why?
| Leukopenia | 1 | 1988 | 28 | 0.020 |
Why?
| Phenylurea Compounds | 1 | 2009 | 89 | 0.020 |
Why?
| Immunophenotyping | 2 | 2000 | 311 | 0.020 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2009 | 182 | 0.020 |
Why?
| False Positive Reactions | 1 | 1988 | 114 | 0.020 |
Why?
| Exercise Therapy | 1 | 2012 | 412 | 0.020 |
Why?
| Electrophoresis | 1 | 1988 | 30 | 0.020 |
Why?
| Macrophages | 2 | 1995 | 1480 | 0.020 |
Why?
| Antigens, Differentiation | 1 | 1988 | 81 | 0.020 |
Why?
| Hospitals, Veterans | 1 | 2009 | 255 | 0.020 |
Why?
| Transfection | 1 | 2010 | 911 | 0.020 |
Why?
| Drug Interactions | 1 | 1990 | 394 | 0.020 |
Why?
| Perilipin-1 | 1 | 2008 | 16 | 0.020 |
Why?
| Estrogen Receptor Modulators | 1 | 2008 | 17 | 0.020 |
Why?
| Staining and Labeling | 1 | 1988 | 141 | 0.020 |
Why?
| S100 Proteins | 1 | 2008 | 36 | 0.020 |
Why?
| Antigens, Surface | 1 | 1988 | 151 | 0.020 |
Why?
| Nervous System Diseases | 1 | 1991 | 252 | 0.020 |
Why?
| Vimentin | 1 | 1988 | 51 | 0.020 |
Why?
| Community Health Services | 1 | 2009 | 227 | 0.020 |
Why?
| Androstadienes | 1 | 2008 | 106 | 0.020 |
Why?
| Central Nervous System | 1 | 1990 | 257 | 0.020 |
Why?
| Genetic Predisposition to Disease | 1 | 2016 | 2282 | 0.020 |
Why?
| Sarcoma, Kaposi | 1 | 1988 | 76 | 0.020 |
Why?
| Bone Marrow Purging | 2 | 1996 | 3 | 0.020 |
Why?
| Lung Diseases | 2 | 1992 | 742 | 0.020 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 1279 | 0.020 |
Why?
| Clinical Trials, Phase II as Topic | 2 | 2000 | 72 | 0.020 |
Why?
| Academic Medical Centers | 1 | 2009 | 481 | 0.020 |
Why?
| Biomarkers | 1 | 2018 | 3973 | 0.020 |
Why?
| Risk | 2 | 2000 | 854 | 0.020 |
Why?
| Heart Diseases | 1 | 1990 | 350 | 0.020 |
Why?
| Gastrointestinal Diseases | 1 | 2008 | 198 | 0.020 |
Why?
| Stem Cell Transplantation | 1 | 2007 | 166 | 0.020 |
Why?
| Phosphoproteins | 1 | 2008 | 332 | 0.020 |
Why?
| Immunoglobulin G | 1 | 1990 | 847 | 0.020 |
Why?
| Bevacizumab | 1 | 2006 | 129 | 0.020 |
Why?
| Quality of Health Care | 1 | 2009 | 608 | 0.010 |
Why?
| Body Mass Index | 1 | 2012 | 2273 | 0.010 |
Why?
| Melanoma | 2 | 1988 | 730 | 0.010 |
Why?
| Carrier Proteins | 1 | 2008 | 743 | 0.010 |
Why?
| Ascites | 1 | 2002 | 44 | 0.010 |
Why?
| Cells, Cultured | 1 | 1990 | 4083 | 0.010 |
Why?
| Brain | 1 | 2014 | 2679 | 0.010 |
Why?
| Phenotype | 1 | 2010 | 3076 | 0.010 |
Why?
| Carcinoma, Lewis Lung | 1 | 2001 | 13 | 0.010 |
Why?
| Carcinoma, Large Cell | 1 | 2001 | 15 | 0.010 |
Why?
| Hemorrhage | 2 | 1998 | 678 | 0.010 |
Why?
| Transplantation Conditioning | 1 | 2002 | 166 | 0.010 |
Why?
| Phytohemagglutinins | 1 | 2000 | 28 | 0.010 |
Why?
| CD4-CD8 Ratio | 1 | 2000 | 22 | 0.010 |
Why?
| Hypersensitivity, Delayed | 1 | 2000 | 28 | 0.010 |
Why?
| Lymphocyte Culture Test, Mixed | 1 | 2000 | 50 | 0.010 |
Why?
| Drug Synergism | 1 | 2001 | 371 | 0.010 |
Why?
| Microcomputers | 1 | 2000 | 16 | 0.010 |
Why?
| Skin Tests | 1 | 2000 | 100 | 0.010 |
Why?
| Graft vs Host Disease | 1 | 2002 | 241 | 0.010 |
Why?
| France | 1 | 2000 | 29 | 0.010 |
Why?
| Louisiana | 1 | 2000 | 27 | 0.010 |
Why?
| Philadelphia | 1 | 2000 | 47 | 0.010 |
Why?
| Immunoglobulins | 1 | 2000 | 159 | 0.010 |
Why?
| Automation | 1 | 2000 | 82 | 0.010 |
Why?
| Immunity | 1 | 2000 | 139 | 0.010 |
Why?
| Personnel Selection | 1 | 1980 | 72 | 0.010 |
Why?
| Lung | 1 | 1992 | 3930 | 0.010 |
Why?
| Marriage | 1 | 1980 | 114 | 0.010 |
Why?
| Lipopolysaccharide Receptors | 1 | 1999 | 87 | 0.010 |
Why?
| Heart Failure | 1 | 1992 | 2150 | 0.010 |
Why?
| Thalassemia | 1 | 1998 | 6 | 0.010 |
Why?
| Interleukin-4 | 1 | 1999 | 212 | 0.010 |
Why?
| Multicenter Studies as Topic | 1 | 2000 | 286 | 0.010 |
Why?
| Receptors, Purinergic P1 | 1 | 1998 | 26 | 0.010 |
Why?
| Pilot Projects | 2 | 1994 | 1587 | 0.010 |
Why?
| Microscopy, Fluorescence | 1 | 2000 | 400 | 0.010 |
Why?
| Reference Values | 1 | 2000 | 793 | 0.010 |
Why?
| Infant, Newborn | 1 | 2009 | 5762 | 0.010 |
Why?
| Acute Disease | 1 | 2001 | 980 | 0.010 |
Why?
| Filgrastim | 1 | 1997 | 7 | 0.010 |
Why?
| Killer Cells, Natural | 1 | 2000 | 427 | 0.010 |
Why?
| Adenoviruses, Human | 1 | 1996 | 26 | 0.010 |
Why?
| Pregnancy | 1 | 2009 | 6402 | 0.010 |
Why?
| Heparin | 1 | 1998 | 253 | 0.010 |
Why?
| Lymphoma, B-Cell | 1 | 1998 | 105 | 0.010 |
Why?
| Tissue Plasminogen Activator | 1 | 1998 | 222 | 0.010 |
Why?
| Freezing | 1 | 1996 | 86 | 0.010 |
Why?
| Lymphocyte Activation | 1 | 2000 | 1106 | 0.010 |
Why?
| Lymphocyte Depletion | 1 | 1996 | 131 | 0.010 |
Why?
| Genes, Reporter | 1 | 1996 | 267 | 0.010 |
Why?
| Carcinoma, Squamous Cell | 1 | 2001 | 626 | 0.010 |
Why?
| Drug Tolerance | 1 | 1995 | 90 | 0.010 |
Why?
| Reticulocyte Count | 1 | 1994 | 6 | 0.010 |
Why?
| Kidney Function Tests | 1 | 1995 | 152 | 0.010 |
Why?
| Topotecan | 1 | 1994 | 12 | 0.010 |
Why?
| Incidence | 1 | 2001 | 2644 | 0.010 |
Why?
| Antigens, CD | 1 | 1996 | 489 | 0.010 |
Why?
| Registries | 1 | 2002 | 1896 | 0.010 |
Why?
| Liver | 1 | 2002 | 1839 | 0.010 |
Why?
| Urinary Bladder Diseases | 1 | 1993 | 18 | 0.010 |
Why?
| Glioblastoma | 1 | 1996 | 326 | 0.010 |
Why?
| Heart | 1 | 1997 | 637 | 0.010 |
Why?
| Flow Cytometry | 1 | 1996 | 1156 | 0.010 |
Why?
| Boston | 1 | 1993 | 87 | 0.010 |
Why?
| Chromatography, High Pressure Liquid | 1 | 1995 | 582 | 0.010 |
Why?
| Iron | 1 | 1994 | 288 | 0.010 |
Why?
| Palliative Care | 1 | 1998 | 725 | 0.010 |
Why?
| Cell Line | 1 | 1996 | 2781 | 0.010 |
Why?
| Immunologic Factors | 1 | 1993 | 231 | 0.010 |
Why?
| Cystitis | 1 | 1990 | 22 | 0.010 |
Why?
| Introns | 1 | 1990 | 251 | 0.000 |
Why?
| Metabolic Clearance Rate | 1 | 1989 | 118 | 0.000 |
Why?
| Prostatic Neoplasms | 1 | 1996 | 1016 | 0.000 |
Why?
| Platinum | 1 | 1989 | 44 | 0.000 |
Why?
| Drug Combinations | 1 | 1990 | 330 | 0.000 |
Why?
| Brain Diseases | 1 | 1990 | 137 | 0.000 |
Why?
| Macrophage-1 Antigen | 1 | 1988 | 28 | 0.000 |
Why?
| Bone Marrow Examination | 1 | 1988 | 6 | 0.000 |
Why?
| Infant | 1 | 2002 | 9024 | 0.000 |
Why?
| Platelet Count | 1 | 1988 | 82 | 0.000 |
Why?
| Erythrocyte Count | 1 | 1988 | 19 | 0.000 |
Why?
| Methods | 1 | 1988 | 64 | 0.000 |
Why?
| Pelvic Neoplasms | 1 | 1988 | 19 | 0.000 |
Why?
| Erythroblasts | 1 | 1988 | 15 | 0.000 |
Why?
| DNA Damage | 1 | 1990 | 384 | 0.000 |
Why?
| Acute Kidney Injury | 1 | 1995 | 790 | 0.000 |
Why?
| Fever | 1 | 1988 | 298 | 0.000 |
Why?
| Pneumonia | 1 | 1992 | 616 | 0.000 |
Why?
| In Vitro Techniques | 1 | 1988 | 1085 | 0.000 |
Why?
| Statistics as Topic | 1 | 1987 | 307 | 0.000 |
Why?
|
|
Elias's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|